nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—lung cancer—thymus cancer	0.854	1	CtDrD
Erlotinib—Ischaemia—Octreotide—thymus cancer	0.00517	0.0855	CcSEcCtD
Erlotinib—Nail disorder—Octreotide—thymus cancer	0.00291	0.0481	CcSEcCtD
Erlotinib—Peptic ulcer—Octreotide—thymus cancer	0.00282	0.0467	CcSEcCtD
Erlotinib—Acne—Octreotide—thymus cancer	0.00224	0.0371	CcSEcCtD
Erlotinib—Cellulitis—Octreotide—thymus cancer	0.00207	0.0343	CcSEcCtD
Erlotinib—Drug interaction—Octreotide—thymus cancer	0.00203	0.0336	CcSEcCtD
Erlotinib—JAK3—hematopoietic system—thymus cancer	0.00189	0.0258	CbGeAlD
Erlotinib—Neuropathy—Octreotide—thymus cancer	0.00177	0.0293	CcSEcCtD
Erlotinib—FLT3—hematopoietic system—thymus cancer	0.00149	0.0203	CbGeAlD
Erlotinib—LTK—lung—thymus cancer	0.00137	0.0187	CbGeAlD
Erlotinib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00137	0.0227	CcSEcCtD
Erlotinib—JAK3—lymphoid tissue—thymus cancer	0.00133	0.0181	CbGeAlD
Erlotinib—AURKC—thyroid gland—thymus cancer	0.00131	0.0178	CbGeAlD
Erlotinib—TNK1—pituitary gland—thymus cancer	0.00129	0.0175	CbGeAlD
Erlotinib—ULK3—hematopoietic system—thymus cancer	0.00129	0.0175	CbGeAlD
Erlotinib—Dehydration—Octreotide—thymus cancer	0.00127	0.0211	CcSEcCtD
Erlotinib—Dry skin—Octreotide—thymus cancer	0.00126	0.0208	CcSEcCtD
Erlotinib—Gastritis—Octreotide—thymus cancer	0.00121	0.02	CcSEcCtD
Erlotinib—MKNK1—hematopoietic system—thymus cancer	0.00121	0.0165	CbGeAlD
Erlotinib—JAK3—thyroid gland—thymus cancer	0.00121	0.0165	CbGeAlD
Erlotinib—Pancreatitis—Octreotide—thymus cancer	0.00116	0.0192	CcSEcCtD
Erlotinib—TNK1—thyroid gland—thymus cancer	0.00111	0.0151	CbGeAlD
Erlotinib—JAK3—lung—thymus cancer	0.0011	0.015	CbGeAlD
Erlotinib—Weight decreased—Octreotide—thymus cancer	0.00107	0.0177	CcSEcCtD
Erlotinib—Pneumonia—Octreotide—thymus cancer	0.00106	0.0176	CcSEcCtD
Erlotinib—ABL2—pituitary gland—thymus cancer	0.00106	0.0144	CbGeAlD
Erlotinib—Depression—Octreotide—thymus cancer	0.00105	0.0174	CcSEcCtD
Erlotinib—FLT3—lymphoid tissue—thymus cancer	0.00105	0.0143	CbGeAlD
Erlotinib—Neuropathy peripheral—Octreotide—thymus cancer	0.00103	0.0171	CcSEcCtD
Erlotinib—Conjunctivitis—Octreotide—thymus cancer	0.00103	0.017	CcSEcCtD
Erlotinib—PIP4K2C—cardiac atrium—thymus cancer	0.00102	0.0139	CbGeAlD
Erlotinib—TNK1—lung—thymus cancer	0.00101	0.0137	CbGeAlD
Erlotinib—PIP4K2C—pituitary gland—thymus cancer	0.001	0.0136	CbGeAlD
Erlotinib—MAP3K19—lung—thymus cancer	0.000998	0.0136	CbGeAlD
Erlotinib—Hepatobiliary disease—Octreotide—thymus cancer	0.000998	0.0165	CcSEcCtD
Erlotinib—STK10—hematopoietic system—thymus cancer	0.000997	0.0136	CbGeAlD
Erlotinib—Epistaxis—Octreotide—thymus cancer	0.000996	0.0165	CcSEcCtD
Erlotinib—ULK3—cardiac atrium—thymus cancer	0.000977	0.0133	CbGeAlD
Erlotinib—FLT3—bone marrow—thymus cancer	0.000956	0.013	CbGeAlD
Erlotinib—ULK3—pituitary gland—thymus cancer	0.000954	0.013	CbGeAlD
Erlotinib—Hepatitis—Octreotide—thymus cancer	0.000947	0.0157	CcSEcCtD
Erlotinib—UGT1A1—hematopoietic system—thymus cancer	0.000942	0.0128	CbGeAlD
Erlotinib—LTK—lymph node—thymus cancer	0.00094	0.0128	CbGeAlD
Erlotinib—MKNK1—cardiac atrium—thymus cancer	0.00092	0.0125	CbGeAlD
Erlotinib—ABL2—thyroid gland—thymus cancer	0.000911	0.0124	CbGeAlD
Erlotinib—MKNK1—pituitary gland—thymus cancer	0.000898	0.0122	CbGeAlD
Erlotinib—EGFR—thyroid gland—thymus cancer	0.000889	0.0121	CbGeAlD
Erlotinib—SLK—cardiac atrium—thymus cancer	0.000871	0.0119	CbGeAlD
Erlotinib—FLT3—lung—thymus cancer	0.000866	0.0118	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—thymus cancer	0.000864	0.0118	CbGeAlD
Erlotinib—PIP4K2C—thyroid gland—thymus cancer	0.000862	0.0117	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—thymus cancer	0.000853	0.0116	CbGeAlD
Erlotinib—SLK—pituitary gland—thymus cancer	0.000851	0.0116	CbGeAlD
Erlotinib—Arrhythmia—Octreotide—thymus cancer	0.000846	0.014	CcSEcCtD
Erlotinib—Alopecia—Octreotide—thymus cancer	0.000837	0.0138	CcSEcCtD
Erlotinib—Mental disorder—Octreotide—thymus cancer	0.00083	0.0137	CcSEcCtD
Erlotinib—ABL2—lung—thymus cancer	0.000827	0.0113	CbGeAlD
Erlotinib—ULK3—bone marrow—thymus cancer	0.000825	0.0112	CbGeAlD
Erlotinib—Erythema—Octreotide—thymus cancer	0.000825	0.0136	CcSEcCtD
Erlotinib—Malnutrition—Octreotide—thymus cancer	0.000825	0.0136	CcSEcCtD
Erlotinib—ULK3—thyroid gland—thymus cancer	0.000823	0.0112	CbGeAlD
Erlotinib—Flatulence—Octreotide—thymus cancer	0.000813	0.0134	CcSEcCtD
Erlotinib—AURKC—lymph node—thymus cancer	0.000811	0.011	CbGeAlD
Erlotinib—EGFR—lung—thymus cancer	0.000807	0.011	CbGeAlD
Erlotinib—Back pain—Octreotide—thymus cancer	0.000798	0.0132	CcSEcCtD
Erlotinib—PIP4K2C—lung—thymus cancer	0.000783	0.0107	CbGeAlD
Erlotinib—MKNK1—bone marrow—thymus cancer	0.000776	0.0106	CbGeAlD
Erlotinib—MKNK1—thyroid gland—thymus cancer	0.000774	0.0105	CbGeAlD
Erlotinib—JAK3—lymph node—thymus cancer	0.000751	0.0102	CbGeAlD
Erlotinib—ULK3—lung—thymus cancer	0.000747	0.0102	CbGeAlD
Erlotinib—Syncope—Octreotide—thymus cancer	0.00074	0.0122	CcSEcCtD
Erlotinib—SLK—bone marrow—thymus cancer	0.000735	0.01	CbGeAlD
Erlotinib—SLK—thyroid gland—thymus cancer	0.000733	0.00999	CbGeAlD
Erlotinib—Loss of consciousness—Octreotide—thymus cancer	0.000725	0.012	CcSEcCtD
Erlotinib—ORM1—hematopoietic system—thymus cancer	0.000723	0.00985	CbGeAlD
Erlotinib—Cough—Octreotide—thymus cancer	0.00072	0.0119	CcSEcCtD
Erlotinib—MKNK1—lung—thymus cancer	0.000703	0.00958	CbGeAlD
Erlotinib—Myalgia—Octreotide—thymus cancer	0.000702	0.0116	CcSEcCtD
Erlotinib—Chest pain—Octreotide—thymus cancer	0.000702	0.0116	CcSEcCtD
Erlotinib—Arthralgia—Octreotide—thymus cancer	0.000702	0.0116	CcSEcCtD
Erlotinib—STK10—lymphoid tissue—thymus cancer	0.000702	0.00956	CbGeAlD
Erlotinib—Anxiety—Octreotide—thymus cancer	0.0007	0.0116	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000697	0.0115	CcSEcCtD
Erlotinib—SLCO2B1—hematopoietic system—thymus cancer	0.000693	0.00944	CbGeAlD
Erlotinib—TNK1—lymph node—thymus cancer	0.00069	0.00939	CbGeAlD
Erlotinib—ABL1—hematopoietic system—thymus cancer	0.000687	0.00935	CbGeAlD
Erlotinib—MAP2K5—cardiac atrium—thymus cancer	0.000676	0.00921	CbGeAlD
Erlotinib—Oedema—Octreotide—thymus cancer	0.000673	0.0111	CcSEcCtD
Erlotinib—Infection—Octreotide—thymus cancer	0.000669	0.0111	CcSEcCtD
Erlotinib—SLK—lung—thymus cancer	0.000666	0.00907	CbGeAlD
Erlotinib—Shock—Octreotide—thymus cancer	0.000662	0.011	CcSEcCtD
Erlotinib—MAP2K5—pituitary gland—thymus cancer	0.000661	0.00899	CbGeAlD
Erlotinib—Nervous system disorder—Octreotide—thymus cancer	0.00066	0.0109	CcSEcCtD
Erlotinib—Thrombocytopenia—Octreotide—thymus cancer	0.000659	0.0109	CcSEcCtD
Erlotinib—Skin disorder—Octreotide—thymus cancer	0.000654	0.0108	CcSEcCtD
Erlotinib—Anorexia—Octreotide—thymus cancer	0.000642	0.0106	CcSEcCtD
Erlotinib—STK10—bone marrow—thymus cancer	0.000639	0.0087	CbGeAlD
Erlotinib—STK10—thyroid gland—thymus cancer	0.000638	0.00868	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000613	0.0101	CcSEcCtD
Erlotinib—Insomnia—Octreotide—thymus cancer	0.000609	0.0101	CcSEcCtD
Erlotinib—Dyspnoea—Octreotide—thymus cancer	0.0006	0.00993	CcSEcCtD
Erlotinib—FLT3—lymph node—thymus cancer	0.000593	0.00807	CbGeAlD
Erlotinib—Dyspepsia—Octreotide—thymus cancer	0.000593	0.0098	CcSEcCtD
Erlotinib—Decreased appetite—Octreotide—thymus cancer	0.000585	0.00968	CcSEcCtD
Erlotinib—CYP1B1—hematopoietic system—thymus cancer	0.000582	0.00792	CbGeAlD
Erlotinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000581	0.00961	CcSEcCtD
Erlotinib—Fatigue—Octreotide—thymus cancer	0.00058	0.0096	CcSEcCtD
Erlotinib—STK10—lung—thymus cancer	0.000579	0.00789	CbGeAlD
Erlotinib—Constipation—Octreotide—thymus cancer	0.000576	0.00952	CcSEcCtD
Erlotinib—Pain—Octreotide—thymus cancer	0.000576	0.00952	CcSEcCtD
Erlotinib—MAP2K5—thyroid gland—thymus cancer	0.000569	0.00775	CbGeAlD
Erlotinib—ABL2—lymph node—thymus cancer	0.000566	0.0077	CbGeAlD
Erlotinib—EGFR—lymph node—thymus cancer	0.000552	0.00752	CbGeAlD
Erlotinib—Gastrointestinal pain—Octreotide—thymus cancer	0.00055	0.00911	CcSEcCtD
Erlotinib—PIP4K2C—lymph node—thymus cancer	0.000535	0.00729	CbGeAlD
Erlotinib—Body temperature increased—Octreotide—thymus cancer	0.000532	0.0088	CcSEcCtD
Erlotinib—Abdominal pain—Octreotide—thymus cancer	0.000532	0.0088	CcSEcCtD
Erlotinib—ABL1—cardiac atrium—thymus cancer	0.000522	0.0071	CbGeAlD
Erlotinib—MAP2K5—lung—thymus cancer	0.000517	0.00704	CbGeAlD
Erlotinib—ULK3—lymph node—thymus cancer	0.000511	0.00696	CbGeAlD
Erlotinib—ABL1—pituitary gland—thymus cancer	0.00051	0.00694	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—thymus cancer	0.000484	0.00659	CbGeAlD
Erlotinib—Asthenia—Octreotide—thymus cancer	0.000483	0.00799	CcSEcCtD
Erlotinib—MKNK1—lymph node—thymus cancer	0.000481	0.00655	CbGeAlD
Erlotinib—Pruritus—Octreotide—thymus cancer	0.000476	0.00788	CcSEcCtD
Erlotinib—ORM1—bone marrow—thymus cancer	0.000464	0.00631	CbGeAlD
Erlotinib—Diarrhoea—Octreotide—thymus cancer	0.000461	0.00762	CcSEcCtD
Erlotinib—SLK—lymph node—thymus cancer	0.000456	0.0062	CbGeAlD
Erlotinib—CYP2C8—hematopoietic system—thymus cancer	0.000446	0.00607	CbGeAlD
Erlotinib—Dizziness—Octreotide—thymus cancer	0.000445	0.00736	CcSEcCtD
Erlotinib—SLCO2B1—thyroid gland—thymus cancer	0.000443	0.00603	CbGeAlD
Erlotinib—ABL1—bone marrow—thymus cancer	0.00044	0.006	CbGeAlD
Erlotinib—ABL1—thyroid gland—thymus cancer	0.000439	0.00598	CbGeAlD
Erlotinib—CYP1B1—pituitary gland—thymus cancer	0.000432	0.00588	CbGeAlD
Erlotinib—Vomiting—Octreotide—thymus cancer	0.000428	0.00708	CcSEcCtD
Erlotinib—Rash—Octreotide—thymus cancer	0.000424	0.00702	CcSEcCtD
Erlotinib—Dermatitis—Octreotide—thymus cancer	0.000424	0.00701	CcSEcCtD
Erlotinib—Headache—Octreotide—thymus cancer	0.000422	0.00698	CcSEcCtD
Erlotinib—ORM1—lung—thymus cancer	0.00042	0.00572	CbGeAlD
Erlotinib—CYP1A2—hematopoietic system—thymus cancer	0.000417	0.00568	CbGeAlD
Erlotinib—CYP1A1—hematopoietic system—thymus cancer	0.000411	0.0056	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—thymus cancer	0.00041	0.00558	CbGeAlD
Erlotinib—SLCO2B1—lung—thymus cancer	0.000402	0.00548	CbGeAlD
Erlotinib—CYP3A5—hematopoietic system—thymus cancer	0.000402	0.00548	CbGeAlD
Erlotinib—Nausea—Octreotide—thymus cancer	0.0004	0.00661	CcSEcCtD
Erlotinib—ABL1—lung—thymus cancer	0.000399	0.00543	CbGeAlD
Erlotinib—STK10—lymph node—thymus cancer	0.000396	0.00539	CbGeAlD
Erlotinib—CYP1A1—epithelium—thymus cancer	0.000376	0.00512	CbGeAlD
Erlotinib—CYP1B1—thyroid gland—thymus cancer	0.000372	0.00507	CbGeAlD
Erlotinib—MAP2K5—lymph node—thymus cancer	0.000354	0.00482	CbGeAlD
Erlotinib—CYP1B1—lung—thymus cancer	0.000338	0.0046	CbGeAlD
Erlotinib—CYP2C8—pituitary gland—thymus cancer	0.000331	0.0045	CbGeAlD
Erlotinib—ABCG2—pituitary gland—thymus cancer	0.000321	0.00438	CbGeAlD
Erlotinib—CYP1A1—cardiac atrium—thymus cancer	0.000312	0.00425	CbGeAlD
Erlotinib—CYP3A4—hematopoietic system—thymus cancer	0.000302	0.00411	CbGeAlD
Erlotinib—CYP2D6—hematopoietic system—thymus cancer	0.000297	0.00404	CbGeAlD
Erlotinib—ORM1—lymph node—thymus cancer	0.000287	0.00391	CbGeAlD
Erlotinib—ABCG2—bone marrow—thymus cancer	0.000278	0.00378	CbGeAlD
Erlotinib—ABCG2—thyroid gland—thymus cancer	0.000277	0.00377	CbGeAlD
Erlotinib—SLCO2B1—lymph node—thymus cancer	0.000275	0.00375	CbGeAlD
Erlotinib—ABL1—lymph node—thymus cancer	0.000273	0.00372	CbGeAlD
Erlotinib—CYP1A2—thyroid gland—thymus cancer	0.000267	0.00363	CbGeAlD
Erlotinib—CYP1A1—thyroid gland—thymus cancer	0.000263	0.00358	CbGeAlD
Erlotinib—ALB—lymph node—thymus cancer	0.000252	0.00343	CbGeAlD
Erlotinib—ABCG2—lung—thymus cancer	0.000252	0.00343	CbGeAlD
Erlotinib—CYP1A2—lung—thymus cancer	0.000242	0.0033	CbGeAlD
Erlotinib—CYP1A1—lung—thymus cancer	0.000239	0.00325	CbGeAlD
Erlotinib—CYP3A5—lung—thymus cancer	0.000234	0.00318	CbGeAlD
Erlotinib—CYP1B1—lymph node—thymus cancer	0.000231	0.00315	CbGeAlD
Erlotinib—ABCB1—hematopoietic system—thymus cancer	0.000214	0.00291	CbGeAlD
Erlotinib—ABCB1—epithelium—thymus cancer	0.000195	0.00266	CbGeAlD
Erlotinib—ABCG2—lymph node—thymus cancer	0.000172	0.00234	CbGeAlD
Erlotinib—CYP1A1—lymph node—thymus cancer	0.000163	0.00222	CbGeAlD
Erlotinib—ABCB1—pituitary gland—thymus cancer	0.000158	0.00216	CbGeAlD
Erlotinib—ABCB1—lymphoid tissue—thymus cancer	0.00015	0.00205	CbGeAlD
Erlotinib—ABCB1—bone marrow—thymus cancer	0.000137	0.00186	CbGeAlD
Erlotinib—ABCB1—thyroid gland—thymus cancer	0.000137	0.00186	CbGeAlD
Erlotinib—ABCB1—lung—thymus cancer	0.000124	0.00169	CbGeAlD
Erlotinib—EGFR—Bladder Cancer—CDKN2A—thymus cancer	0.00011	0.00893	CbGpPWpGaD
Erlotinib—ABL1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	0.00011	0.00892	CbGpPWpGaD
Erlotinib—MKNK1—Signaling by FGFR—KIT—thymus cancer	0.000109	0.00888	CbGpPWpGaD
Erlotinib—ABL1—TP53 Network—TP53—thymus cancer	0.000106	0.0086	CbGpPWpGaD
Erlotinib—JAK3—CD40/CD40L signaling—AKT1—thymus cancer	0.000105	0.00851	CbGpPWpGaD
Erlotinib—TNK1—Focal Adhesion—AKT1—thymus cancer	0.000103	0.0084	CbGpPWpGaD
Erlotinib—JAK3—IL2 signaling events mediated by PI3K—AKT1—thymus cancer	0.000102	0.00832	CbGpPWpGaD
Erlotinib—MKNK1—Signaling by FGFR in disease—KIT—thymus cancer	0.000102	0.00827	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—DPYSL5—thymus cancer	9.68e-05	0.00788	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways in Glioblastoma—CDKN2A—thymus cancer	9.39e-05	0.00764	CbGpPWpGaD
Erlotinib—JAK3—IL-2 Signaling Pathway—AKT1—thymus cancer	9.24e-05	0.00752	CbGpPWpGaD
Erlotinib—NR1I2—Generic Transcription Pathway—MAML2—thymus cancer	9.12e-05	0.00743	CbGpPWpGaD
Erlotinib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	8.74e-05	0.00712	CbGpPWpGaD
Erlotinib—ABCB1—lymph node—thymus cancer	8.49e-05	0.00116	CbGeAlD
Erlotinib—JAK3—G beta:gamma signalling through PI3Kgamma—AKT1—thymus cancer	8.3e-05	0.00676	CbGpPWpGaD
Erlotinib—ABL1—Validated transcriptional targets of TAp63 isoforms—CDKN2A—thymus cancer	8.23e-05	0.0067	CbGpPWpGaD
Erlotinib—JAK3—GPVI-mediated activation cascade—AKT1—thymus cancer	8.17e-05	0.00665	CbGpPWpGaD
Erlotinib—JAK3—Signaling by Interleukins—IL2—thymus cancer	8e-05	0.00652	CbGpPWpGaD
Erlotinib—JAK3—G-protein beta:gamma signalling—AKT1—thymus cancer	7.91e-05	0.00644	CbGpPWpGaD
Erlotinib—JAK3—Oncostatin M Signaling Pathway—TP53—thymus cancer	7.72e-05	0.00628	CbGpPWpGaD
Erlotinib—ABL1—p53 pathway—CDKN2A—thymus cancer	7.67e-05	0.00624	CbGpPWpGaD
Erlotinib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	7.63e-05	0.00621	CbGpPWpGaD
Erlotinib—JAK3—IL-4 Signaling Pathway—AKT1—thymus cancer	7.56e-05	0.00615	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	7.11e-05	0.00579	CbGpPWpGaD
Erlotinib—EGFR—E-cadherin signaling in keratinocytes—AKT1—thymus cancer	7.04e-05	0.00573	CbGpPWpGaD
Erlotinib—ABL1—Regulation of retinoblastoma protein—CDKN2A—thymus cancer	7.01e-05	0.00571	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	6.93e-05	0.00564	CbGpPWpGaD
Erlotinib—JAK3—IL4-mediated signaling events—AKT1—thymus cancer	6.77e-05	0.00551	CbGpPWpGaD
Erlotinib—JAK3—Oncostatin M Signaling Pathway—AKT1—thymus cancer	6.52e-05	0.0053	CbGpPWpGaD
Erlotinib—EGFR—Bladder Cancer—TP53—thymus cancer	6.1e-05	0.00497	CbGpPWpGaD
Erlotinib—EGFR—Gastric Cancer Network 2—TP53—thymus cancer	6.1e-05	0.00497	CbGpPWpGaD
Erlotinib—MAP2K5—Cardiac Hypertrophic Response—AKT1—thymus cancer	6.07e-05	0.00494	CbGpPWpGaD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—thymus cancer	5.97e-05	0.00486	CbGpPWpGaD
Erlotinib—ABL1—Regulation of Telomerase—IL2—thymus cancer	5.93e-05	0.00483	CbGpPWpGaD
Erlotinib—ABL1—ATM Signaling Pathway—TP53—thymus cancer	5.82e-05	0.00474	CbGpPWpGaD
Erlotinib—EGFR—SHP2 signaling—IL2—thymus cancer	5.76e-05	0.00469	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	5.53e-05	0.0045	CbGpPWpGaD
Erlotinib—ABCG2—Fluoropyrimidine Activity—TP53—thymus cancer	5.42e-05	0.00441	CbGpPWpGaD
Erlotinib—EGFR—PI-3K cascade—KIT—thymus cancer	5.38e-05	0.00438	CbGpPWpGaD
Erlotinib—EGFR—Extracellular vesicle-mediated signaling in recipient cells—AKT1—thymus cancer	5.29e-05	0.00431	CbGpPWpGaD
Erlotinib—EGFR—PI3K/AKT activation—KIT—thymus cancer	5.25e-05	0.00427	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways in Glioblastoma—TP53—thymus cancer	5.22e-05	0.00425	CbGpPWpGaD
Erlotinib—EGFR—GAB1 signalosome—KIT—thymus cancer	5.21e-05	0.00424	CbGpPWpGaD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—thymus cancer	5.09e-05	0.00414	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Telomerase—IL2—thymus cancer	5.07e-05	0.00413	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—CDKN2A—thymus cancer	5.04e-05	0.0041	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—CDKN2A—thymus cancer	4.95e-05	0.00403	CbGpPWpGaD
Erlotinib—MKNK1—MAPK Signaling Pathway—TP53—thymus cancer	4.79e-05	0.0039	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CYLD—thymus cancer	4.73e-05	0.00385	CbGpPWpGaD
Erlotinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	4.73e-05	0.00385	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—CDKN2A—thymus cancer	4.69e-05	0.00382	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MAML2—thymus cancer	4.6e-05	0.00374	CbGpPWpGaD
Erlotinib—ABL1—ErbB Signaling Pathway—TP53—thymus cancer	4.58e-05	0.00373	CbGpPWpGaD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—IL2—thymus cancer	4.51e-05	0.00367	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	4.41e-05	0.00359	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MAML2—thymus cancer	4.39e-05	0.00357	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	4.38e-05	0.00356	CbGpPWpGaD
Erlotinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	4.33e-05	0.00352	CbGpPWpGaD
Erlotinib—ABL1—p53 pathway—TP53—thymus cancer	4.27e-05	0.00347	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—KIT—thymus cancer	4.25e-05	0.00346	CbGpPWpGaD
Erlotinib—MKNK1—Signaling by FGFR—AKT1—thymus cancer	4.16e-05	0.00339	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CYLD—thymus cancer	4.16e-05	0.00338	CbGpPWpGaD
Erlotinib—MKNK1—MAPK Signaling Pathway—AKT1—thymus cancer	4.04e-05	0.00329	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—KIT—thymus cancer	4.02e-05	0.00327	CbGpPWpGaD
Erlotinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—thymus cancer	3.93e-05	0.0032	CbGpPWpGaD
Erlotinib—EGFR—ErbB Signaling Pathway—TP53—thymus cancer	3.92e-05	0.00319	CbGpPWpGaD
Erlotinib—MKNK1—Signaling by FGFR in disease—AKT1—thymus cancer	3.88e-05	0.00316	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—KIT—thymus cancer	3.85e-05	0.00313	CbGpPWpGaD
Erlotinib—EGFR—a6b1 and a6b4 Integrin signaling—AKT1—thymus cancer	3.83e-05	0.00311	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response—TP53—thymus cancer	3.81e-05	0.0031	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—KIT—thymus cancer	3.79e-05	0.00308	CbGpPWpGaD
Erlotinib—MAP2K5—Integrin-mediated Cell Adhesion—AKT1—thymus cancer	3.76e-05	0.00306	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—IL2—thymus cancer	3.74e-05	0.00304	CbGpPWpGaD
Erlotinib—ABL1—miRNA Regulation of DNA Damage Response—TP53—thymus cancer	3.68e-05	0.003	CbGpPWpGaD
Erlotinib—MAP2K5—ErbB1 downstream signaling—AKT1—thymus cancer	3.62e-05	0.00295	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—KIT—thymus cancer	3.62e-05	0.00294	CbGpPWpGaD
Erlotinib—ABL1—p53 pathway—AKT1—thymus cancer	3.6e-05	0.00293	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KIT—thymus cancer	3.6e-05	0.00293	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—KIT—thymus cancer	3.58e-05	0.00291	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KIT—thymus cancer	3.56e-05	0.0029	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CYLD—thymus cancer	3.55e-05	0.00289	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	3.51e-05	0.00286	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by PTP1B—AKT1—thymus cancer	3.41e-05	0.00277	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	3.35e-05	0.00273	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—KIT—thymus cancer	3.35e-05	0.00273	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—KIT—thymus cancer	3.35e-05	0.00273	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KIT—thymus cancer	3.32e-05	0.0027	CbGpPWpGaD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—thymus cancer	3.29e-05	0.00268	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KIT—thymus cancer	3.29e-05	0.00268	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KIT—thymus cancer	3.28e-05	0.00267	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—IL2—thymus cancer	3.26e-05	0.00266	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MAML2—thymus cancer	3.22e-05	0.00262	CbGpPWpGaD
Erlotinib—ABL1—Regulation of Telomerase—AKT1—thymus cancer	3.22e-05	0.00262	CbGpPWpGaD
Erlotinib—EGFR—Thromboxane A2 receptor signaling—AKT1—thymus cancer	3.21e-05	0.00261	CbGpPWpGaD
Erlotinib—ABL1—Retinoblastoma (RB) in Cancer—TP53—thymus cancer	3.13e-05	0.00255	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KIT—thymus cancer	3.1e-05	0.00252	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IL2—thymus cancer	2.99e-05	0.00243	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	2.97e-05	0.00242	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TP53—thymus cancer	2.94e-05	0.0024	CbGpPWpGaD
Erlotinib—EGFR—LPA receptor mediated events—AKT1—thymus cancer	2.89e-05	0.00235	CbGpPWpGaD
Erlotinib—EGFR—AGE/RAGE pathway—AKT1—thymus cancer	2.82e-05	0.00229	CbGpPWpGaD
Erlotinib—MAP2K5—BDNF signaling pathway—AKT1—thymus cancer	2.81e-05	0.00229	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—TP53—thymus cancer	2.8e-05	0.00228	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	2.79e-05	0.00227	CbGpPWpGaD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—AKT1—thymus cancer	2.78e-05	0.00226	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—TP53—thymus cancer	2.75e-05	0.00224	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Telomerase—AKT1—thymus cancer	2.75e-05	0.00224	CbGpPWpGaD
Erlotinib—ABCG2—HIF-1-alpha transcription factor network—AKT1—thymus cancer	2.63e-05	0.00214	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—thymus cancer	2.61e-05	0.00213	CbGpPWpGaD
Erlotinib—MAP2K5—Insulin Signaling—AKT1—thymus cancer	2.58e-05	0.0021	CbGpPWpGaD
Erlotinib—MAP2K5—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	2.56e-05	0.00208	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—AKT1—thymus cancer	2.48e-05	0.00202	CbGpPWpGaD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.45e-05	0.00199	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAML2—thymus cancer	2.43e-05	0.00198	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CYLD—thymus cancer	2.42e-05	0.00197	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	2.37e-05	0.00193	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—IL2—thymus cancer	2.33e-05	0.00189	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD8A—thymus cancer	2.31e-05	0.00188	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KIT—thymus cancer	2.28e-05	0.00186	CbGpPWpGaD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	2.28e-05	0.00185	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IL2—thymus cancer	2.27e-05	0.00185	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—AKT1—thymus cancer	2.25e-05	0.00183	CbGpPWpGaD
Erlotinib—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thymus cancer	2.24e-05	0.00183	CbGpPWpGaD
Erlotinib—EGFR—Androgen receptor signaling pathway—AKT1—thymus cancer	2.22e-05	0.0018	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—AKT1—thymus cancer	2.21e-05	0.0018	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—thymus cancer	2.19e-05	0.00178	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KIT—thymus cancer	2.12e-05	0.00173	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.11e-05	0.00172	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—thymus cancer	2.09e-05	0.0017	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CYLD—thymus cancer	2.07e-05	0.00168	CbGpPWpGaD
Erlotinib—EGFR—PI-3K cascade—AKT1—thymus cancer	2.05e-05	0.00167	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—thymus cancer	2.01e-05	0.00164	CbGpPWpGaD
Erlotinib—EGFR—PI3K/AKT activation—AKT1—thymus cancer	2e-05	0.00163	CbGpPWpGaD
Erlotinib—EGFR—GAB1 signalosome—AKT1—thymus cancer	1.99e-05	0.00162	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAML2—thymus cancer	1.98e-05	0.00161	CbGpPWpGaD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	1.94e-05	0.00158	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—AKT1—thymus cancer	1.94e-05	0.00158	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—thymus cancer	1.92e-05	0.00156	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—AKT1—thymus cancer	1.86e-05	0.00152	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—thymus cancer	1.83e-05	0.00149	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KIT—thymus cancer	1.73e-05	0.00141	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—thymus cancer	1.72e-05	0.0014	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—AKT1—thymus cancer	1.7e-05	0.00138	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.67e-05	0.00136	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD8A—thymus cancer	1.67e-05	0.00136	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—thymus cancer	1.62e-05	0.00132	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—AKT1—thymus cancer	1.62e-05	0.00132	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	1.61e-05	0.00131	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—thymus cancer	1.58e-05	0.00129	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—AKT1—thymus cancer	1.57e-05	0.00128	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—AKT1—thymus cancer	1.53e-05	0.00125	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KIT—thymus cancer	1.52e-05	0.00124	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAML2—thymus cancer	1.52e-05	0.00123	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—thymus cancer	1.49e-05	0.00122	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KIT—thymus cancer	1.49e-05	0.00121	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—IL2—thymus cancer	1.47e-05	0.0012	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—AKT1—thymus cancer	1.47e-05	0.00119	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—AKT1—thymus cancer	1.45e-05	0.00118	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—AKT1—thymus cancer	1.44e-05	0.00118	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.43e-05	0.00116	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	1.42e-05	0.00116	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.41e-05	0.00115	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—AKT1—thymus cancer	1.38e-05	0.00112	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—AKT1—thymus cancer	1.37e-05	0.00112	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	1.37e-05	0.00112	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—AKT1—thymus cancer	1.37e-05	0.00111	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—AKT1—thymus cancer	1.36e-05	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	1.34e-05	0.00109	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL2—thymus cancer	1.34e-05	0.00109	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—AKT1—thymus cancer	1.33e-05	0.00109	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—thymus cancer	1.33e-05	0.00108	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KIT—thymus cancer	1.3e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	1.28e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—AKT1—thymus cancer	1.28e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—AKT1—thymus cancer	1.28e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—AKT1—thymus cancer	1.27e-05	0.00103	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—AKT1—thymus cancer	1.26e-05	0.00103	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—AKT1—thymus cancer	1.26e-05	0.00102	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—AKT1—thymus cancer	1.25e-05	0.00102	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KIT—thymus cancer	1.25e-05	0.00102	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL2—thymus cancer	1.22e-05	0.000993	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—AKT1—thymus cancer	1.21e-05	0.000984	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.2e-05	0.000979	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IL2—thymus cancer	1.19e-05	0.000969	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—AKT1—thymus cancer	1.18e-05	0.000963	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—thymus cancer	1.18e-05	0.000962	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—thymus cancer	1.17e-05	0.000949	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IL2—thymus cancer	1.14e-05	0.000926	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.13e-05	0.000922	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KIT—thymus cancer	1.12e-05	0.000912	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAML2—thymus cancer	1.06e-05	0.000865	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL2—thymus cancer	1.05e-05	0.000851	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—thymus cancer	1.01e-05	0.000822	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—thymus cancer	9.96e-06	0.000811	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—thymus cancer	9.56e-06	0.000778	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KIT—thymus cancer	9.14e-06	0.000744	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KIT—thymus cancer	8.88e-06	0.000722	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—AKT1—thymus cancer	8.71e-06	0.000709	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKT1—thymus cancer	8.1e-06	0.000659	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—thymus cancer	7.97e-06	0.000649	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—thymus cancer	7.89e-06	0.000642	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—thymus cancer	7.74e-06	0.00063	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—thymus cancer	7.65e-06	0.000623	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIT—thymus cancer	7.58e-06	0.000617	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—thymus cancer	7.24e-06	0.000589	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	7.19e-06	0.000585	CbGpPWpGaD
Erlotinib—EGFR—Disease—KIT—thymus cancer	7e-06	0.00057	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—thymus cancer	6.79e-06	0.000553	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—thymus cancer	6.72e-06	0.000547	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—thymus cancer	6.62e-06	0.000538	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—thymus cancer	6.58e-06	0.000536	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—thymus cancer	6.46e-06	0.000526	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—thymus cancer	6.43e-06	0.000523	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—thymus cancer	6.25e-06	0.000508	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—thymus cancer	6.17e-06	0.000502	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	6.07e-06	0.000494	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—thymus cancer	5.86e-06	0.000477	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—thymus cancer	5.84e-06	0.000475	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—thymus cancer	5.82e-06	0.000473	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—thymus cancer	5.8e-06	0.000472	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—thymus cancer	5.67e-06	0.000462	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—thymus cancer	5.63e-06	0.000458	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—thymus cancer	5.36e-06	0.000436	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—thymus cancer	5.34e-06	0.000434	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—thymus cancer	5.07e-06	0.000412	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—thymus cancer	4.97e-06	0.000404	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—thymus cancer	4.9e-06	0.000399	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—thymus cancer	4.77e-06	0.000388	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—thymus cancer	4.28e-06	0.000348	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—thymus cancer	4.13e-06	0.000336	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—thymus cancer	3.77e-06	0.000306	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	3.49e-06	0.000284	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—thymus cancer	3.45e-06	0.000281	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—thymus cancer	3.39e-06	0.000276	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—thymus cancer	3.18e-06	0.000259	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—thymus cancer	3.17e-06	0.000258	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—thymus cancer	2.89e-06	0.000236	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—thymus cancer	2.67e-06	0.000217	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—thymus cancer	2.46e-06	0.0002	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—thymus cancer	2.3e-06	0.000187	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—thymus cancer	2.22e-06	0.00018	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—thymus cancer	2.09e-06	0.00017	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—thymus cancer	1.87e-06	0.000152	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—thymus cancer	1.5e-06	0.000122	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—thymus cancer	1.41e-06	0.000115	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—thymus cancer	1.3e-06	0.000106	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—thymus cancer	1.29e-06	0.000105	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—thymus cancer	1.13e-06	9.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—thymus cancer	1.06e-06	8.66e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—thymus cancer	9.02e-07	7.34e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—thymus cancer	6.96e-07	5.66e-05	CbGpPWpGaD
